OKYO Pharma Ltd ADR
$ 1.66
4.40%
17 Apr - close price
- Market Cap 83,442,000 USD
- Current Price $ 1.66
- High / Low $ 1.70 / 1.57
- Stock P/E N/A
- Book Value -0.09
- EPS -0.10
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.05 %
- ROE -29.69 %
- 52 Week High 3.35
- 52 Week Low 1.14
About
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$8.00
Quarterly Earnings
| Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-08-05 | 2025-03-31 | 2025-01-29 | 2024-09-30 | 2024-07-30 | 2024-03-31 | 2024-01-09 | 2023-12-28 | 2023-08-15 |
| Reported EPS | 0 | -0.06 | None | -0.08 | None | -0.09 | None | -0.1 | -0.11 | -0.34 |
| Estimated EPS | -0.04 | -0.05 | -0.05 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.11 | -0.11 |
| Surprise | 0.04 | -0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | -0.23 |
| Surprise Percentage | 100% | -20% | None% | 11.1111% | None% | 0% | None% | 0% | 0% | -209.0909% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKYO
2026-04-16 08:09:04
OKYO Pharma Limited (NASDAQ:OKYO) experienced a 25.0% decline in short interest during March, reducing the total to 206,345 shares, representing approximately 0.9% of the company's shares. This translates to a days-to-cover ratio of 2.2 days based on average trading volume. Institutional investors like Renaissance Technologies, Citadel Advisors, and XTX Topco have been active, with overall institutional ownership at about 2.97%.
2026-04-08 05:40:43
OKYO Pharma announced a Scientific Advisory Board (SAB) meeting will be held during the 2026 ASCRS Annual Meeting to review clinical data for its lead candidate, urcosimod, and guide its clinical program. Concurrently, Dr. Pedram Hamrah will present Phase 2 efficacy and safety results for urcosimod in neuropathic corneal pain (NCP) at ASCRS. This dual presence marks a significant milestone for OKYO Pharma as it prepares for the next clinical trial of urcosimod, which has Fast Track designation for NCP, a condition currently lacking FDA-approved therapies.
2026-04-08 05:38:47
OKYO Pharma will hold a Scientific Advisory Board meeting with ophthalmology experts and present urcosimod data at the 2026 ASCRS Annual Meeting. The meeting will review clinical data for urcosimod, a lead candidate for neuropathic corneal pain, and refine the clinical strategy for its next trial. Dr. Pedram Hamrah will present Phase 2 study results for urcosimod, which has Fast Track designation from the FDA for neuropathic corneal pain.
2026-04-08 05:38:47
OKYO Pharma (NASDAQ:OKYO) is set to host a Scientific Advisory Board meeting during the 2026 American Society of Cataract and Refractive Surgery Annual Meeting to discuss their lead candidate, urcosimod. The company is preparing to initiate a 150-patient Phase 2b/3 study for neuropathic corneal pain in the first half of 2026, following positive Phase 2a results. Despite a recent stock pullback, analysts see significant upside potential, though InvestingPro indicates the stock may be overvalued relative to its Fair Value.
2026-04-07 10:39:13
OKYO Pharma is highlighting progress for its lead eye therapy, urcosimod, by presenting Phase 2 data and convening a Scientific Advisory Board meeting around the 2026 ASCRS meeting. The company plans to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026 to further evaluate urcosimod for neuropathic corneal pain, for which it holds an IND and FDA Fast Track designation. The data presentation and SAB meeting aim to validate the clinical program and leverage expert guidance for the next trials.
2026-04-07 10:39:13
OKYO Pharma (Nasdaq: OKYO) is holding a Scientific Advisory Board meeting and presenting Phase 2 data for its lead candidate, urcosimod, at the 2026 ASCRS Annual Meeting. The company plans to initiate the next clinical trial for urcosimod, which has FDA Fast Track designation and an IND for neuropathic corneal pain, in the first half of 2026. This presentation and meeting are critical steps to refine the clinical strategy for urcosimod, addressing a significant unmet need for patients with neuropathic corneal pain.
